Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease.
暂无分享,去创建一个
M. Woodward | A. Jenkins | S. MacMahon | J. Chalmers | B. Neal | B. Kemp | Anushka Patel | D. Campbell | S. Colman | D. Campbell
[1] Simon Davies,et al. Epidemiology: Study Design and Data Analysis (2nd ed.) , 2006 .
[2] M. Woodward,et al. Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke , 2005, Stroke.
[3] M. Woodward,et al. Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease , 2005, Circulation.
[4] P. Hildebrandt,et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.
[5] P. Hildebrandt,et al. N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults , 2005 .
[6] M. Woodward,et al. Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease , 2005, Hypertension.
[7] B. Psaty,et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups , 2004, Neurology.
[8] M. Woodward,et al. Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific Region , 2004, Circulation.
[9] M. Tremblay,et al. Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.D300041-JLR200 , 2004, Journal of Lipid Research.
[10] K. Yano,et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program. , 2004, American journal of epidemiology.
[11] D. Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .
[12] C. Anderson,et al. Ten-Year Risk of First Recurrent Stroke and Disability After First-Ever Stroke in the Perth Community Stroke Study , 2004, Stroke.
[13] L. Chambless,et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.
[14] M. Woodward,et al. Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History: The PROGRESS Trial , 2003, Stroke.
[15] J. Michael Gaziano,et al. Cholesterol and the Risk of Ischemic Stroke , 2003, Stroke.
[16] Progress. Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease A Randomized Controlled Trial , 2003 .
[17] M. Woodward,et al. Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease: A Randomized Controlled Trial , 2003, Stroke.
[18] À. Rovira,et al. C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease , 2003, Stroke.
[19] Mark Woodward,et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. , 2003, International journal of epidemiology.
[20] T. Truelsen,et al. Homocysteine and Risk of Recurrent Stroke , 2003, Stroke.
[21] K. Yano,et al. C-Reactive Protein and the Future Risk of Thromboembolic Stroke in Healthy Men , 2003, Circulation.
[22] A. Hofman,et al. Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study , 2003, Journal of neurology, neurosurgery, and psychiatry.
[23] P. Ridker,et al. Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women , 2002, Circulation.
[24] P. Ridker,et al. Inflammatory bio‐markers and cardiovascular risk prediction , 2002, Journal of internal medicine.
[25] Konrad Jamrozik,et al. Long-Term Disability After First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study, 1989–1990 , 2002, Stroke.
[26] Natalia S. Rost,et al. Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.
[27] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[28] G. Hankey,et al. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations* , 1999, The Lancet.
[29] R W Alexander,et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. , 1999, Circulation.
[30] Mark Woodward,et al. Epidemiology: Study Design and Data Analysis , 1999 .
[31] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[32] R. Crooks,et al. Assay of plasma homocysteine: light sensitivity of the fluorescent 7-benzo-2-oxa-1, 3-diazole-4-sulfonic acid derivative, and use of appropriate calibrators. , 1996, Clinical chemistry.
[33] J. Ubbink,et al. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. , 1991, Journal of chromatography.